Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two Replagal dosing regimens in adults with Fabry disease
2007-005543-22Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2008
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of agalsidase alfa in Fabry disease (FD) (2 arms), sponsored by Takeda. Primary endpoint: Change in left ventricular mass index (LVM/height). Started Jan 2008; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2007-005543-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005543-22.